GPC sobre Prevención del Ictus - GuÃaSalud
GPC sobre Prevención del Ictus - GuÃaSalud
GPC sobre Prevención del Ictus - GuÃaSalud
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
542. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for<br />
Secondary Prevention in Elderly Patients: A Hierarchical Bayesian Meta-Analysis.<br />
J Am Coll Cardiol. 2008;51:37-45.<br />
543. Hayward RA, Hofer TP, Vijan S. Narrative review: lack of evidence for recommended<br />
low-density lipoprotein treatment targets: a solvable problem.Ann Intern Med.<br />
2006 Oct 3;145(7):520-30.<br />
544. Scottish Intercollegiate Gui<strong>del</strong>ines Network (SIGN). Risk estimation and the prevention<br />
of cardiovascular disease. Edinburgh: SIGN; 2007 [Consultado el 17 Marzo<br />
2008]. SIGN Publication No 97. Disponible en: http://www.sign.ac.uk/pdf/sign97.pdf<br />
545. San Vicente Blanco R, Pérez Irazusta I, Ibarra Amarica J, Berraondo Zabalegui I,<br />
Uribe Oyarbide F, Urraca García de Madinabeitia J, et al. Guía de Práctica<br />
Clínica <strong>sobre</strong> el manejo de los lípidos como factor de riesgo cardiovascular.<br />
Osakidetza.<strong>GPC</strong> 2008/1.Vitoria-Gasteiz.<br />
546. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular<br />
disease: a systematic review and meta-analysis. BJOG. 2006;113(1):5-14.<br />
547. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial<br />
of estrogen-replacement therapy after ischemic stroke. N Engl J Med.<br />
2001;345:1243-49.<br />
548. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, et al. Antiphospholipid<br />
antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke.<br />
JAMA. 2004;291(5):576-84.<br />
549. Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, et al. Warfarin-<br />
Aspirin Recurrent Stroke Study Group: A comparison of warfarin and aspirin for<br />
the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444-51.<br />
550. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al.<br />
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke,<br />
myocardial infarction, and death: the Vitamin Intervention for Stroke<br />
Prevention (VISP) randomized controlled trial. JAMA. 2004;291(5):565-75.<br />
551. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet<br />
Neurol. 2007;6(9):830-8.<br />
552. Vitatops Trial Study Group. The VITATOPS (Vitamins to Prevent Stroke) Trial:<br />
rationale and design of an international, large, simple, randomised trial of homocysteine-lowering<br />
multivitamin therapy in patients with recent transient ischaemic<br />
attack or stroke. Cerebrovasc Dis. 2002;13(2):120-6.<br />
553. B-Vitamin Treatmen Trialists’ Collaboration. Homocysteine-lowering trials for prevention<br />
of cardiovascular events: a review of the design and power of the large randomized<br />
trials. Am Heart J. 2006;151(2):282-7.<br />
554. Sandercock P, Bamford J, Dennis M, Burn J, Slattery J, Jones L, et al. Atrial fibrillation<br />
and stroke: prevalence in different types of stroke and inuence on early and long<br />
term prognosis (Oxfordshire Community Stroke Project). BMJ. 1992;305:1460-5.<br />
238 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS
Change language